Many modern vaccines and future immunotherapies require adjuvants, and there is a recognized need for newer and more diverse choices and even new cellular technologies like VLP.

CBI-3A is a novel VLP that elicits immune responses from all three elements of the adaptive immune system but is particularly adept at stimulating the innate immune response. It has been studied in multiple animal species with a variety of antigens against multiple pathogens. This versatility makes it a valuable tool for addressing key industry challenges (involving patient populations with impaired immune systems, the limited immunogenicity of recombinant antigens, pathogens that require broad and complex immune responses, and vaccine supply constraints.)